JP2021525771A5 - - Google Patents

Info

Publication number
JP2021525771A5
JP2021525771A5 JP2020567199A JP2020567199A JP2021525771A5 JP 2021525771 A5 JP2021525771 A5 JP 2021525771A5 JP 2020567199 A JP2020567199 A JP 2020567199A JP 2020567199 A JP2020567199 A JP 2020567199A JP 2021525771 A5 JP2021525771 A5 JP 2021525771A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525771A (ja
JP7351859B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035247 external-priority patent/WO2019236496A1/en
Publication of JP2021525771A publication Critical patent/JP2021525771A/ja
Publication of JP2021525771A5 publication Critical patent/JP2021525771A5/ja
Application granted granted Critical
Publication of JP7351859B2 publication Critical patent/JP7351859B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567199A 2018-06-04 2019-06-03 Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物 Active JP7351859B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680324P 2018-06-04 2018-06-04
US62/680,324 2018-06-04
PCT/US2019/035247 WO2019236496A1 (en) 2018-06-04 2019-06-03 Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7

Publications (3)

Publication Number Publication Date
JP2021525771A JP2021525771A (ja) 2021-09-27
JP2021525771A5 true JP2021525771A5 (cg-RX-API-DMAC7.html) 2022-06-06
JP7351859B2 JP7351859B2 (ja) 2023-09-27

Family

ID=66913097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567199A Active JP7351859B2 (ja) 2018-06-04 2019-06-03 Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物

Country Status (7)

Country Link
US (1) US10857153B2 (cg-RX-API-DMAC7.html)
EP (1) EP3802519A1 (cg-RX-API-DMAC7.html)
JP (1) JP7351859B2 (cg-RX-API-DMAC7.html)
CN (1) CN112513031A (cg-RX-API-DMAC7.html)
AR (1) AR114910A1 (cg-RX-API-DMAC7.html)
TW (1) TW202003475A (cg-RX-API-DMAC7.html)
WO (1) WO2019236496A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
JP7351859B2 (ja) 2018-06-04 2023-09-27 アプロス セラピューティクス, インコーポレイテッド Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
JP4667543B2 (ja) 1996-07-03 2011-04-13 大日本住友製薬株式会社 新規プリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ES2284200T3 (es) 1997-02-12 2007-11-01 Electrophoretics Limited Marcadores proteicos para cancer de pulmon y uso de los mismos.
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JP4375901B2 (ja) 1997-11-28 2009-12-02 大日本住友製薬株式会社 新規な複素環化合物
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
JP2009542645A (ja) * 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
AU2010250923A1 (en) 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
CA2871589C (en) * 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
KR102300861B1 (ko) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
WO2018106606A1 (en) 2016-12-05 2018-06-14 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
JP7351859B2 (ja) 2018-06-04 2023-09-27 アプロス セラピューティクス, インコーポレイテッド Tlr7の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物

Similar Documents

Publication Publication Date Title
JP6771512B2 (ja) 抗不安薬組成物、製剤および使用方法
JP6827948B2 (ja) 呼吸器疾患の治療
JP2019089775A (ja) 高濃度の一酸化窒素の投与法
JP2018199684A5 (cg-RX-API-DMAC7.html)
RU2018138195A (ru) Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2013531056A5 (cg-RX-API-DMAC7.html)
JP2019534270A5 (cg-RX-API-DMAC7.html)
CN113038944A (zh) 色甘酸钠和α-乳糖的粉末化制剂
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2020502215A (ja) Task−1およびtask−3チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用
UA119774C2 (uk) Комбінації формотеролу і будесоніду для лікування хронічної обструктивної хвороби легень (хохл)
JP2005508963A (ja) 喘息を治療するためのサルメテロールとフルチカゾンプロピオネートを含む医薬の組み合せ
JP2025501309A5 (cg-RX-API-DMAC7.html)
RU2012125043A (ru) Ингаляционные растворы
RU2015129076A (ru) Арилалкил- и арилоксиалкил-замещенные соединения, блокирующие эпителиальный натриевый канал
JP2022535920A5 (cg-RX-API-DMAC7.html)
JP2019505596A5 (cg-RX-API-DMAC7.html)
JP2023524064A5 (cg-RX-API-DMAC7.html)
RU2010120806A (ru) Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
US9795561B2 (en) Combination of umeclidinium, fluticasone propionate and salmeterol xinafoate for use in the treatment of inflammatory or respiratory tract diseases
JP2011500731A5 (cg-RX-API-DMAC7.html)
ES2917879T3 (es) Nuevo uso de aclidinio
TW200412945A (en) Quaternary ammonium compounds